Key result
Five months of lipid-lowering therapy fails to improve coronary flow reserve in hypercholesterolemic patients.
Why the study?
The coronary flow reserve is reduced in hypercholesterolemic patients and has been reported to improve after lipid-lowering therapy, but changes assessed by transthoracic Doppler echocardiography needed evaluation.
Does lipid-lowering therapy improve coronary flow reserve in hypercholesterolemic patients with no other modifiable risk factors?
Observational (n=14)
Does lipid-lowering therapy improve coronary flow reserve in hypercholesterolemic patients with no other modifiable risk factors?
Absolute Event Rate: 2.5% vs 2.4%
p-value: p=0.875
Five months of lipid-lowering therapy significantly reduced cholesterol levels but did not improve coronary flow reserve in hypercholesterolemic patients without other risk factors.
CFR changes after lipid-lowering may be trackable noninvasively; leaves open whether this alters management or outcomes in hypercholesterolemia.
Background:The coronary flow reserve is known to be reduced in patients with hypercholesterolemia, and has also been reported to improve after lipid-lowering therapy. Using transthoracic Doppler echocardiography, the changes in the coronary flow reserve were evaluated after lipid-lowering therapy in hypercholesterolemic patients. Methods:The coronary flow reserve was determined by pulsed-wave Doppler examination at the distal left anterior descending coronary artery before and after five months of lipid-lowering therapy in 14 hypercholesterolemic patients (total cholesterol ≥230 mg/dL) with no other modifiable risk factors of coronary heart disease. Results:In all patients, the total cholesterol and low-density lipoprotein (LDL) cholesterol were significantly decreased after therapy (from 273±27 mg/dL to 199±22 mg/dL, p=0.001, from 182±25 mg/dL to 110±27 mg/dL, p=0.001, respectively). However, there was no significant change in the coronary flow reserve after lipid-lowering therapy (from 2.4±0.5 to 2.5±0.5, p=0.875). The Baseline LDL-cholesterol showed an inverse correlation with the baseline coronary flow reserve (r =-0.649, p=0.012). Conclusions:In the present study, no significant change in the coronary flow reserve was noted after lipid-lowering therapy in hypercholesterolemic patients with no other risk factors of coronary heart disease, although the baseline LDL-cholesterol levels were found to correlate well with the baseline coronary flow reserve. Transthoracic Doppler echocardiography can be used to easily and non-invasively evaluate the changes in the coronary flow velocity, coronary flow reserve and other related parameters. Therefore, a controlled trial using transthoracic Doppler echocardiography relating to the effect of lipid-lowering therapy on patients showing a wider range of baseline risk factors and LDL
No takes yet. Share an insight, caveat, or question.
Kim et al. (2004) conducted an observational in Hypercholesterolemia (n=14). Lipid-lowering therapy vs. Baseline (before therapy) was evaluated on Coronary flow reserve (p=0.875). Five months of lipid-lowering therapy did not significantly change coronary flow reserve in hypercholesterolemic patients compared to baseline (2.5 vs 2.4, p=0.875).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: